hotspot -WSS

hotspot

author：explore 2025-09-05 09:17:56 - browse：7864

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Bacterial infection may be ‘key event’ in endometriosis, study says

WSS

Congress extends some pandemic preparedness programs

European officials brace for rough respiratory virus season

European officials brace for rough respiratory virus season

Connecting traumatic brain injury and domestic violence

Van's Gluten Free Original Waffles recalled for possible wheat allergen

6 solutions to address cancer drug shortages and others

entertainment

hotspot

hotspot

At least 13 dead in Texas as scorching temps continue

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Listen: Biogen's messy board & Laronde's data problem

DIEP, the 'gold standard' of breast reconstruction, is under threat

IVG is promising — but it won’t replace IVF quite yet

Wildfire smoke exposes gaps in outdoor worker protections

IVG is promising — but it won’t replace IVF quite yet

Medical records are filled with copy

The Karikó problem: Lessons for funding basic research

knowledge

Bacterial infection may be ‘key event’ in endometriosis, study says

Health insurers' Q3 question: how much care are people getting?

IVG is promising — but it won’t replace IVF quite yet

Medicare innovation center doesn’t save money, experts say

Lawsuit highlights wrinkle for disputes over surprise medical bills

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

focus

focus

hotspot

Wikipedia